Forty years experience of treating cancer of unknown primary
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:13Z | |
dc.date.available | 2018-06-22T09:54:13Z | |
dc.date.issued | 2007 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42249 | |
dc.description.abstract | Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists of different favourable and unfavourable sub-sets, treatment of each clinicopathological entity requires a unique approach. The spectrum of therapeutic management includes both locoregional and systemic therapy and should intend to offer optimal benefit to favourable CUP patients and palliative care to unfavourable cases. This review article provides both a historical outline of CUP treatment as well as a helpful therapeutic guide to every oncologist who treats CUP patients. © 2007 Taylor & Francis. | en |
dc.language.iso | eng | en |
dc.source | Acta Oncologica | en |
dc.subject | Bleomycin | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Cisplatin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Dacarbazine | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Neoplasms | en |
dc.subject | Vinblastine | en |
dc.subject | Vincristine | en |
dc.subject | Humans | en |
dc.subject | Mammography | en |
dc.subject | Oncology | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Computer assisted tomography | en |
dc.subject | Paclitaxel | en |
dc.subject | Platinum derivative | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Gemcitabine | en |
dc.subject | Monotherapy | en |
dc.subject | Navelbine | en |
dc.subject | Taxane derivative | en |
dc.subject | Docetaxel | en |
dc.subject | Erlotinib | en |
dc.subject | Metastasis | en |
dc.subject | Cancer diagnosis | en |
dc.subject | Survival rate | en |
dc.subject | Carmustine | en |
dc.subject | Epirubicin | en |
dc.subject | Folinic acid | en |
dc.subject | Irinotecan | en |
dc.subject | Conference paper | en |
dc.subject | Axillary lymph node | en |
dc.subject | Mitomycin c | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Oncogene | en |
dc.subject | Drug megadose | en |
dc.subject | Carcinogenesis | en |
dc.subject | Prostate cancer | en |
dc.subject | Pathology | en |
dc.subject | Lymphadenopathy | en |
dc.subject | Nuclear magnetic resonance imaging | en |
dc.subject | Treatment response | en |
dc.subject | Anthracycline derivative | en |
dc.subject | Bevacizumab | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Altretamine | en |
dc.subject | Practice guideline | en |
dc.subject | Squamous cell carcinoma | en |
dc.subject | Combination chemotherapy | en |
dc.subject | Unknown primary | en |
dc.subject | Angiogenesis | en |
dc.subject | Cancer palliative therapy | en |
dc.subject | Prostate specific antigen | en |
dc.subject | Neuroendocrine tumor | en |
dc.subject | Cervical lymph node | en |
dc.subject | Peritoneum cancer | en |
dc.subject | Multimodality cancer therapy | en |
dc.subject | Medical specialist | en |
dc.subject | Drug dose comparison | en |
dc.subject | Chromosome aberration | en |
dc.subject | Tumor suppressor gene | en |
dc.subject | Protein degradation | en |
dc.subject | Cancer epidemiology | en |
dc.subject | Blast cell crisis | en |
dc.subject | Cancer of unknown primary | en |
dc.subject | Granulocyte colony stimulating factor receptor | en |
dc.subject | Papillary carcinoma | en |
dc.subject | Sparfosic acid | en |
dc.title | Forty years experience of treating cancer of unknown primary | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1080/02841860701243095 | |
dc.description.volume | 46 | |
dc.description.issue | 5 | |
dc.description.startingpage | 592 | |
dc.description.endingpage | 601 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |